Lineage Cell Therapeutics, Inc. (LCTX)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Lineage Cell Therapeutics, Inc. (LCTX) is listed on NYSE American, where it has traded since March 5, 1992.
- Listed On
- NYSE American
- Listed Since
- March 5, 1992
- Employees
- 77
- Market Cap
- $263M
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 127 institutions reported holding LCTX, with 116.4 million shares worth $152.5 million in aggregate. The largest reported holder was Broadwood Capital, with 49.6 million shares worth $64.9 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Broadwood Capital | 49,560,992 | $65M | Unchanged |
| BlackRock | 13,186,895 | $17M | Added 241.21% |
| Vanguard | 12,082,653 | $16M | Added 24.2% |
| Defender Capital, LLC | 6,598,899 | $9M | Reduced 1.94% |
| Geode Capital Management | 5,299,457 | $7M | Added 110.04% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is LCTX?
Lineage Cell Therapeutics, Inc. (LCTX) is listed on NYSE American, where it has traded since March 5, 1992.
Who are the largest institutional holders of LCTX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of LCTX were Broadwood Capital, BlackRock and Vanguard.
How many institutions own LCTX?
127 institutions reported a position in LCTX for the quarter ended June 30, 2026, worth $152.5 million in total.
Did institutions buy or sell LCTX last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for LCTX.
Every reported institutional holder, plus insider and congressional trades in LCTX, on SentiSense.